Answers are grounded in this paper and cite their sources.
Purpose Cancer of the nasal vestibule (CNV) differs anatomically and clinically from both sinonasal and cutaneous squamous cell carcinoma, yet lacks formal recognition as a separate clinical entity and topographical subsite; whether it is also biologically distinct has not yet been investigated. EUSICA/INSICA advocates for formal recognition of CNV and a unified classification, treatment, and translational framework. Method Published literature on CNV, including population‐based cohorts, T‐classification studies, brachytherapy outcomes, and quality‐of‐life data, was reviewed by an international multidisciplinary EUSICA/INSICA expert panel to formulate consensus recommendations. Finding CNV shows favorable outcomes, drains preferentially to facial and submandibular nodes, and is amenable to organ‐preserving radiotherapy, in particular brachytherapy. It is staged using four non‐uniform systems; multicenter validation in 609 patients from 21 centers supported the prognostic utility of the New Rome classification integrated with clinical nodal status. Validated CNV‐specific quality‐of‐life instruments are lacking. Compared with NCCN‐defined high‐risk cutaneous SCC of the nose, CNV differs in topography, pattern of local spread, prognostic landmarks, nodal behavior, and treatment paradigm. Comparative molecular data versus cutaneous and sinonasal SCC are not yet available. Conclusion EUSICA/INSICA calls for formal recognition of CNV as a distinct ICD‐O‐3 subsite, incorporation of the New Rome T classification into UICC/AJCC TNM, standardized organ‐preserving treatment, and dedicated translational research, including comparative molecular studies to determine whether its clinical distinctness has a biological basis.
No takes yet. Share an insight, caveat, or question.
Ridder et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: